Benign Prostatic Hyperplasia Treatment Devices Market Size, Share & Trends Analysis Report By Treatment, By Procedure, By Product (Resectoscopes, Urology Laser), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Benign Prostatic Hyperplasia Treatment Devices Market Size, Share & Trends Analysis Report By Treatment, By Procedure, By Product (Resectoscopes, Urology Laser), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Benign Prostatic Hyperplasia Treatment Devices Market Growth & Trends

The global benign prostatic hyperplasia treatment devices market size is anticipated to reach USD 2.79 billion by 2030, registering at a CAGR of 8.90% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing application of the robotic system used for the benign prostatic hyperplasia (BPH) treatments, enhancements in the aquablation therapy, early disease diagnosis and increasing health awareness among people drive the market growth. Due to the rising prevalence of BPH and the ongoing development of novel therapy alternatives, the BPH treatment device market is anticipated to expand globally.

Aquablation therapy involves the use of a system that combines water and radiofrequency energy. Normally, either local or general anesthesia is used during the surgery. When compared to the open surgical treatments for BPH, aquablation therapy has a number of advantages, including less bleeding and a shorter catheterization period. For instance, in April 2023, according to PROCEPT BioRobotics Corporation, 5-year results from the WATER II Study showed that Aquablation therapy, a minimally invasive robotic surgical procedure for benign prostatic hyperplasia, safely and effectively relieved persistent symptoms in men with large prostates (80 to 150 mL) and maintains sexual function for up to five years. The study, which was released in the Journal of Urology, showed that patients' symptoms and quality of life kept improving significantly over time.

The key players are also involved in developing implants for the treatment of benign prostatic hyperplasia. The positive outcomes from the clinical studies have a positive impact on the market growth. For instance, as per the article published in Urology Times, the company ProVerum Limited invented the nitinol expander device for people with BPH in June 2022. The first treatment using the revolutionary ProVee System was successfully conducted in the key ProVIDE trial at Avant Concierge Urology. A self-expanding implant called ProVee gently reshapes and widens a restricted urethra to increase urine flow shortly after it is in place and also improves the quality of life in the patients. Thus, due to such advancements, the demand for Benign Prostatic Hyperplasia (BPH) treatment devices will increase in the near future.

Benign Prostatic Hyperplasia Treatment Devices Market Report Highlights

• Based on treatment, minimal invasive surgery dominated the BPH treatment devices market with a revenue share of 72.16 % in 2022, owing to the less postpartum pain and discomfort that may result from smaller incisions and less tissue manipulation
• Based on procedure, Transurethral Resection of the Prostate (TURP) segment dominated the market in 2022 with a revenue share of 25.32%. The TURP procedure is considered a golden standard and the most effective BPH treatment
• Based on end-use, hospitals held a majority share of the market with 64.77% in 2022. The increasing number of patients being admitted to hospitals due to surgeries, therapies, and treatments is expected to increase the demand for neurovascular catheters in the near future
• North America led the market with the maximum revenue share of 34.95% in 2022. Rising demand for minimally invasive surgeries and rising government initiatives for improving healthcare infrastructures are among the key factors driving the market growth. In addition, technological advancement and innovation of new noninvasive techniques will create lucrative opportunities for the segment

Please note The report will be delivered in 2-3 business days upon order notification.